Researchers analyzed a large amount of genomic data to reclassify breast cancer patients in a more personalized way, such as the PAM50 classification, which reclassified patients into luminal A, luminal B, HER2-enriched, basal-like and normal like groups [12]. Here, ERBB2 is linked to breast carcinoma.